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When analyzed as a whole, and when stratified by
AUA risk, there was no correlation between average
CCPS deviation and grade change from biopsy to
post-RP pathology. Furthermore, there was no
significant difference between average CCPS
scores in the different grade-change groups. Our
data suggest that the CCPS may not be used to
reliably predict a change in biopsy GS.
Can Prolaris Score be used to predict change in Gleason Score from 
biopsy to post-radical prostatectomy pathology?
REFERENCES
 65 Men underwent radical prostatectomy after Prolaris
analysis between 2015-2017: Table 1
 63% with biopsy GS ≤ 3+4
 49% rate of GS discordance: 21.5% downgraded,
27.7% upgraded
Mean CCPS deviation for each group detailed in Table 2
One-way ANOVA showed no significant difference in
CCPS between grade-change groups (p = 0.5532)
 ANOVA of Intermediate-risk group (n=44) also
showed no significant difference (p = 0.4196)
 7 of 22 with CCPS deviation <-0.3 had GS upgrade and
8 of 15 with deviation -0.2 to 0.2 had GS discordance
(Figure 2)
Mean CCPS deviation in no-change group was within
“consistent” range (-0.18 ± 0.56) but not statistically
different from other groups and had significant deviation
 Intermediate-risk group had nearly even distribution of
CCPS deviation between GS grade-change subgroups
(Figure 3)
Several management options exist for men
with LR and IR PCa
 Decision to undergo surgery vs. surveillance
dependent on degree of risk and patients’ wishes
 High degree of Values-based Patient-centered
Care (VBPCC) required in decision-making
 Genomics shown to alleviate some of mental
treatment burden in PCa patients4
Prognostication with GS high degree of
variance
 Literature discordance rate: 30%1
 Study discordance rate: 49%
Our results do not suggest predictive ability
of CCPS to determine final pathologic GS
 “Consistent” CCPS does not guarantee GS
concordance
 VBPCC conversations able to use GS and CCPS
score as independent risk-stratification tools
 Limitations: smaller than expected sample
size (many more prostatectomies than
genomic tests)
 Will standardize consent for genomic testing in
future protocols
Lehigh Valley Hospital is a large, mixed rural/urban
teaching hospital. For this IRB-approved retrospective
analysis, we evaluated men with PCa who underwent
treatment with RP between 2015 and 2017.
Patients stratified by AUA risk score: low (LR)-,
intermediate (IR)-, and high-risk (HR) groups
Sub-grouped by change in GS: upgraded,
downgraded, or no change, i.e. 3+4  4+3 is an
upgrade
CCPS for each patient normalized with 0=average in
each respective AUA risk group, using information
from Prolaris Score Report (based on data collected
by Myriad Genetics)
 Negative numbers less aggressive, Positive
numbers more aggressive
Mean CCPS deviation for each GS-change subgroup
calculated to assess for correlation between grade-
change and CCPS-predicted risk.
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Problem Statement
 Early detection of prostate cancer (PCa) and the increasing
popularity of active surveillance necessitate the development and
refinement of risk stratification tools.
 While Gleason Score (GS) serves a valuable prognostic role, a
relatively high rate of discordance1 between biopsy and post-
surgical pathology necessitates either additional prognostic tests
or a method to predict the likelihood of grade discrepancy.
 Genomic analysis has emerged as a reliable method to improve
risk stratification for men with prostate cancer, especially for those
with low- and intermediate-risk disease, in whom conservative
management is an option.
 The Cell Cycle Progression Score (CCPS) – or Prolaris Score
(Myriad Genetics) – measures expression of genes involved in
Cell Cycle Progression. It has been validated in numerous settings
as a predictor of cancer-related death and biochemical
recurrence.2,3 The score is used to predict whether an individual’s
cancer is more aggressive, less aggressive, or consistent with
others in his AUA risk group.
 Thus far, the ability of the CCPS to predict a change in GS
between biopsy and post-surgical pathology has not been
evaluated.
In the context of a significant rate of discrepancy in
prostate cancer pathologic grading between biopsy and
post-surgical analysis, this project seeks to determine
whether or not the genomic Cell Cycle Progression Score
can be utilized as a predictor for grade change.
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mean ± sd 62.0 ± 7.2




















-0.8 to -0.3 19 (29.2%)
-0.2 to 0.2 15 (23.1%)
0.3 to 0.8 16 (24.6%) 













Total (N=65) 0.05 ± 0.98 -0.18 ± 0.56 0.04 ± 0.75
AUA High Risk 
(N=9)
-0.22 ± 1.32 
(N=6)
-0.57 ± 0.58 
(N=3)
N/A
AUA Int. Risk 
(N=44)
0.00 ± 0.72 
(N=8)
-0.10 ± 0.58 
(N=23)
0.21 ± 0.75 
(N=13)
AUA Low Risk 
(N=12)
N/A -0.31 ± 0.44 
(N=7)
-0.40 ± 0.61 
(N=5)
Table 2. Average CCPS change for GS grade-change groups
Table 1: Patient characteristics. CCP Scores
normalized to 0=average risk for each individual
AUA risk group
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